Switch theme
Sign up to access all valuation multiples
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
2016
44
LTM Revenue $2.9M
LTM EBITDA -$70.4M
-$18.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Shattuck Labs has a last 12-month revenue (LTM) of $2.9M and a last 12-month EBITDA of -$70.4M.
In the most recent fiscal year, Shattuck Labs achieved revenue of $5.7M and an EBITDA of -$76.7M.
Shattuck Labs expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Shattuck Labs valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.9M | XXX | $5.7M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$70.4M | XXX | -$76.7M | XXX | XXX | XXX |
| EBITDA Margin | -2469% | XXX | -1341% | XXX | XXX | XXX |
| EBIT | -$68.7M | XXX | -$80.6M | XXX | XXX | XXX |
| EBIT Margin | -2408% | XXX | -1408% | XXX | XXX | XXX |
| Net Profit | -$64.2M | XXX | -$75.4M | XXX | XXX | XXX |
| Net Margin | -2252% | XXX | -1318% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Shattuck Labs's stock price is $1.
Shattuck Labs has current market cap of $39.3M, and EV of -$18.4M.
See Shattuck Labs trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$18.4M | $39.3M | XXX | XXX | XXX | XXX | $-1.25 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Shattuck Labs has market cap of $39.3M and EV of -$18.4M.
Shattuck Labs's trades at -3.2x EV/Revenue multiple, and 0.2x EV/EBITDA.
Equity research analysts estimate Shattuck Labs's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Shattuck Labs has a P/E ratio of -0.6x.
See valuation multiples for Shattuck Labs and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $39.3M | XXX | $39.3M | XXX | XXX | XXX |
| EV (current) | -$18.4M | XXX | -$18.4M | XXX | XXX | XXX |
| EV/Revenue | -6.5x | XXX | -3.2x | XXX | XXX | XXX |
| EV/EBITDA | 0.3x | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBIT | 0.3x | XXX | 0.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.6x | XXX | -0.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialShattuck Labs's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $2.0M for the same period.
Shattuck Labs's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Shattuck Labs's rule of X is -2469% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Shattuck Labs and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -2469% | XXX | -1341% | XXX | XXX | XXX |
| EBITDA Growth | -9% | XXX | -16% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -2469% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1175% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1508% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Shattuck Labs acquired XXX companies to date.
Last acquisition by Shattuck Labs was XXXXXXXX, XXXXX XXXXX XXXXXX . Shattuck Labs acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Shattuck Labs founded? | Shattuck Labs was founded in 2016. |
| Where is Shattuck Labs headquartered? | Shattuck Labs is headquartered in United States of America. |
| How many employees does Shattuck Labs have? | As of today, Shattuck Labs has 44 employees. |
| Who is the CEO of Shattuck Labs? | Shattuck Labs's CEO is Dr. Taylor H. Schreiber, M.D.,PhD. |
| Is Shattuck Labs publicy listed? | Yes, Shattuck Labs is a public company listed on NAS. |
| What is the stock symbol of Shattuck Labs? | Shattuck Labs trades under STTK ticker. |
| When did Shattuck Labs go public? | Shattuck Labs went public in 2020. |
| Who are competitors of Shattuck Labs? | Similar companies to Shattuck Labs include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Shattuck Labs? | Shattuck Labs's current market cap is $39.3M |
| What is the current revenue of Shattuck Labs? | Shattuck Labs's last 12 months revenue is $2.9M. |
| What is the current EV/Revenue multiple of Shattuck Labs? | Current revenue multiple of Shattuck Labs is -6.5x. |
| Is Shattuck Labs profitable? | Yes, Shattuck Labs is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Shattuck Labs? | Shattuck Labs's last 12 months EBITDA is -$70.4M. |
| What is Shattuck Labs's EBITDA margin? | Shattuck Labs's last 12 months EBITDA margin is -2469%. |
| What is the current EV/EBITDA multiple of Shattuck Labs? | Current EBITDA multiple of Shattuck Labs is 0.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
